Education
About Us
Working with TipRanks
Follow Us
SOPHiA GENETICS (SOPH)
NASDAQ:SOPH
SOPH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.58 - $4.92
Previous CloseN/A
Volume4.05K
Average Volume (3M)73.44K
Market Cap
$230.45M
Enterprise Value$177.69M
Total Cash (Recent Filing)$94.82M
Total Debt (Recent Filing)$63.81M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Nov 11, 2025EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding67,579,560
10 Day Avg. Volume42,238
30 Day Avg. Volume73,440
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue2.55
Enterprise Value/Gross Profit3.76
Enterprise Value/Ebitda-3.06
Forecast
1Y Price Target
$5.50Price Target Upside69.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Customer GrowthMomentum appears to be building as volume grew with 33 new core genomics customers implemented.
US Market ExpansionUS market expansion continues, where revenue and volumes grew over 30%, indicating strong market penetration.
Bears Say
HeadwindsThe company faced several headwinds in 2024 resulting in below long-term trend growth, notably from a lower biopharma revenue ramp and disruptions in LATAM.
Revenue ChallengesSophia turned in a relatively challenging 2024 as they drove 4% revenue growth while growing their volumes by 11%, which implies a 6-7% decline in revenue per analysis, which declined in part due to headwinds with biopharma customers.
SOPHiA GENETICS News
SOPH FAQ
What was SOPHiA GENETICS’s price range in the past 12 months?
SOPHiA GENETICS lowest stock price was $2.58 and its highest was $4.92 in the past 12 months.
What is SOPHiA GENETICS’s market cap?
SOPHiA GENETICS’s market cap is $230.45M.
When is SOPHiA GENETICS’s upcoming earnings report date?
SOPHiA GENETICS’s upcoming earnings report date is Nov 11, 2025 which is in 66 days.
How were SOPHiA GENETICS’s earnings last quarter?
SOPHiA GENETICS released its earnings results on Aug 05, 2025. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of -$0.214 by -$0.116.
Is SOPHiA GENETICS overvalued?
According to Wall Street analysts SOPHiA GENETICS’s price is currently Undervalued.
Does SOPHiA GENETICS pay dividends?
SOPHiA GENETICS does not currently pay dividends.
What is SOPHiA GENETICS’s EPS estimate?
SOPHiA GENETICS’s EPS estimate is -0.23.
How many shares outstanding does SOPHiA GENETICS have?
SOPHiA GENETICS has 67,579,560 shares outstanding.
What happened to SOPHiA GENETICS’s price movement after its last earnings report?
SOPHiA GENETICS reported an EPS of -$0.33 in its last earnings report, missing expectations of -$0.214. Following the earnings report the stock price went up 3.636%.
Which hedge fund is a major shareholder of SOPHiA GENETICS?
Currently, no hedge funds are holding shares in SOPH
SOPHiA GENETICS Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.50 (69.75% Upside)
$5.50 (69.75% Upside)
Blogger Sentiment
Bullish
SOPH Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.4%
Last 30 Days ▲ 10.5%
Last 30 Days ▲ 10.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.30%
12-Months-Change
Fundamentals
Return on Equity
-74.09%
Trailing 12-Months
Asset Growth
-1.92%
Trailing 12-Months
Company Description
SOPHiA GENETICS
SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.
SOPH Company Deck
SOPH Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth, new customer acquisitions, and a landmark partnership with AstraZeneca, reflecting positive business momentum. However, challenges remain with BioPharma headwinds, increased operating expenses, and regional performance issues in Latin America.View all SOPH earnings summariesSOPH Stock 12 Month Forecast
Average Price Target
$5.50
▲(69.75% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.14% Mutual Funds
20.66% Other Institutional Investors
78.13% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---